The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
Abstract
Background In phase II studies, irinotecan is active in metastatic colorectal cancer, but the overall benefit has not been assessed in a randomised clinical trial. Methods Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio. Findings 189 patients were allocated irinotecan and supportive care and 90 supportive care alone. The mean age of the participants was 58.8 years; 181 (65%) were men and 98 (35%) were women. WHO performance status was 0 in 79 (42%) patients, 1 in 77 (41%) patients, and 2 in 32 (17%) patients. Tumour-related symptoms were present in 134 (71%) patients and weight loss of more than 5% was seen in 15 (8%) patients. With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group. The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001). Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan. In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group. Inte…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trials involving PS 0 to PS 2 patients have shown that chemotherapy groups have a significantly longer survival time than BSC groups that did not receive anticancer drugs [54–56].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [56]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Cancer: Principles and Practice of Oncology
Gunn, W. G. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550100097049 · Cited by 1,307
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
Claus, E. B., Risch, N., & Thompson, W. D. (1994) · Cancer · doi:10.1002/1097-0142(19940201)73:3<643::aid-cncr2820730323>3.0.co;2-5 · Cited by 942
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654
Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., Becouarn, Y., Ychou, M., Marty, M., Extra, J. M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.251 · Cited by 434
Self-citationNordic Gastrointestinal Tumor Adjuvant Therapy Group (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.904 · Cited by 356
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A., Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith, L. S., Eckhardt, S. G., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1128 · Cited by 352
Sources of diagnostic error in fine needle aspiration of the thyroid
Hall, T. L., Layfield, L. J., Philippe, A., & Rosenthal, D. L. (1989) · Cancer · doi:10.1002/1097-0142(19890215)63:4<703::aid-cncr2820630418>3.0.co;2-g · Cited by 277
Research works printed but not linked: 4
- Fages, 1997, Tumor response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer. analysis of data in 455 5FU-resistant patients treated with CPT-11, Proc ASCO, 16, 288a
- Van Cutsem, 1997, Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU, Proc ASCO, 16, 268a
- Kemeny, 1989, Prognostic variables in patients with hepatic metastases from colorectal cancer, Cancer, 63, 742, 10.1002/1097-0142(19890215)63:4<742::AID-CNCR2820630423>3.0.CO;2-T · doi:10.1002/1097-0142(19890215)63:4<742::aid-cncr2820630423>3.0.co;2-t
- Ross, 1996, Chemotherapy for colorectal cancer: relationship between toxicity and quality of life, Ann Oncol, 7, 34
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationThe Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,715
Metadata
- Authors
- Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., & Herait, P.
- Affiliations
- Royal Marsden Hospital (GB)
- Helsinki University Hospital (FI)
- The Christie Hospital (GB)
- Royal Bournemouth Hospital (GB)
- Linköping University Hospital (SE)
- Corresponding author
- Cunningham, David
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1998-10
- Volume
- 352
- Issue
- 9138
- Pages
- 1413-1418
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2096122707
- Cited by
- 1,259
- References
- 18
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 15 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 15 · 2018: 25 · 2017: 17 · 2016: 21 · 2015: 23 · 2014: 30 · 2013: 40 · 2012: 31
- FWCI
- 28.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- irinotecan, metastatic colorectal cancer, supportive care, overall survival, quality of life, weight loss, treatment side effects
- MeSH terms
- Irinotecan, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Agents, Phytogenic, Camptothecin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Palliative Care, Probability, Quality of Life, Colorectal Neoplasms, Survival Analysis, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. https://app.cochat.ai/papers/10.1016/s0140-6736(98)02309-5
- The paper
- Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., & Herait, P. (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet. https://doi.org/10.1016/s0140-6736(98)02309-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.